The present invention relates to novel steroid derivatives that ace on the gamma-aminobutyric acid receptor-chloride ionophore (GR) complex as well as methods for making the same and their applications to induce anesthesia, in the treatment of stress, anxiety, PMS, PND, and seizures such as those caused by epilepsy, to ameliorate or prevent the attacks of anxiety, muscle tension, and depression common with patients suffering from central nervous system abnormalities. The present invention comprises a compound represented by Formula (I): wherein, R, R 1 , R 2 , R 3 , R 4 , R 5 are defined in the description of the invention. The present invention also includes formulations which consist of one or more of the compounds of Formula (I).
1. A compound represented by Formula (I):
including pharmaceutically acceptable esters, salts and acid addition salts thereof, wherein:
R is one of hydrogen, amino, thio, sulfinyl, sulfonyl, sulfonamido, halogen, alkoxy, alkyl, alkenyl, or alkynyl and all R groups can be optionally substituted;
R 1 is one of hydrogen, alkyl, alkenyl, arylkynyl, alkoxyalkyl, aminoalkyl, cyano, cyanoalkyl, thiocyanoalkyl, isothiocyano, azidoalkyl, arylalkyl, arylalkenyl, aryl, arylkylalkynyl, alkanoyloxyalkynyl, heteroaryloxyalkynyl, oxoalkynyl or a ketal thereof, cyanoalkynyl, heteroarylalkynyl, hydroxyalkynyl, alkoxyalkynyl, aminoalkynyl, acylaminoalkynyl, mercaptoalkynyl, hydroxyalkynyl dioic acid hemi-ester or a salt thereof, or alkynyloxyalkynyl and all R 1 groups can be optionally substituted;
R 2 is one of hydroxyl, alkoxy, alkanoyloxy, aminocarbonyloxy, alkoxycarbonyloxy; azido, or NCS;
R 3 is hydrogen, or when a double bond is present between C4 and C5 of the steroid ring system, then R 3 is not present;
R 4 is one of hydrogen or lower alkyl,
R 5 is one of —CH(OR 6 )R 7 , —C≡C-aryl, —C≡C—CH(OR 6 )R 8 , or —C≡C—C(O)R 8 ;
R 6 is independently H, optionally substituted C 1-10 alkyl, optionally substituted C 2-10 alkenyl, optionally substituted C 2-10 alkynyl, optionally substituted aryl, optionally substituted arylkyl, optionally substituted C(O)—C 1-10 alkyl, optionally substituted C(O)—C 2-10 alkenyl, optionally substituted C(O)—C 2-10 alkynyl
R 7 is independently allene, optionally substituted alkynyl, optionally substituted arylkylalkynyl, optionally substituted alkanoyloxyalkynyl, optionally substituted heteroaryloxyalkynyl, oxoalkynyl or a ketal thereof, cyanoalkynyl, hydroxyalkynyl, alkoxyalkynyl, aminoalkynyl, acylaminoalkynyl, mercaptoalkynyl, hydroxyalkynyl dioic acid hemi-ester or a salt thereof, or alkynyloxyalkynyl;
R 8 is independently H, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, arylalkyl, aryl, all of which may be optionally substituted; and
the dotted lines indicate that a single or double bond may be present.
2. A compound represented by Formula (I):
including pharmaceutically acceptable esters, salts and acid addition salts thereof, wherein:
R is one of hydrogen, amino, thio, sulfinyl, sulfonyl, sulfonamido, halogen, alkoxy, alkyl, alkenyl, or alkynyl and all R groups can be optionally substituted;
R 1 is one of alkyl, alkenyl, arylkynyl, alkoxyalkyl, aminoalkyl, cyano, cyanoalkyl, thiocyanoalkyl, isothiocyano, azidoalkyl, arylalkyl, arylalkenyl, aryl, arylkylalkynyl, alkanoyloxyalkynyl, heteroaryloxyalkynyl, oxoalkynyl or a ketal thereof, cyanoalkynyl, heteroarylalkynyl, hydroxyalkynyl, alkoxyalkynyl, aminoalkynyl, acylaminoalkynyl, mercaptoalkynyl, hydroxyalkynyl dioic acid hemi-ester or a salt thereof, or alkynyloxyalkynyl and all R 1 groups can be optionally substituted;
R 2 is one of hydroxyl, alkoxy, alkanoyloxy, aminocarbonyloxy or alkoxycarbonyloxy; azido, or NCS;
R 3 is hydrogen, or when a double bond is present between C4 and C5 of the steroid ring system, then R 3 is not present;
R 4 is one of hydrogen or lower alkyl,
R 5 is —CH(X)—R 6 ; and
X is one of N 3 , CN, or NCS,
R 6 is independently H, optionally substituted C 1-10 alkyl, optionally substituted C 2-10 alkenyl, optionally substituted C 2-10 alkynyl, optionally substituted aryl, optionally substituted arylkyl, optionally substituted C(O)—C 1-10 alkyl, optionally substituted C(O)—C 2-10 alkenyl, optionally substituted C(O)—C 2-10 alkynyl; and the dotted lines indicate that a single or double bond may be present.
3. A compound represented by Formula (I):
including pharmaceutically acceptable esters, salts and acid addition salts thereof, wherein:
R is one of hydrogen, amino, thio, sulfinyl, sulfonyl, sulfonamido, halogen, alkoxy, alkyl, alkenyl, or alkynyl and all R groups can be optionally substituted;
R 1 is one of hydrogen, alkyl, alkenyl, arylkynyl, alkoxyalkyl, aminoalkyl, cyano, cyanoalkyl, thiocyanoalkyl, isothiocyano, azidoalkyl, arylalkyl, arylalkenyl, aryl, arylkylalkynyl, alkanoyloxyalkynyl, heteroaryloxyalkynyl, oxoalkynyl or a ketal thereof, cyanoalkynyl, heteroarylalkynyl, hydroxyalkynyl, alkoxyalkynyl, aminoalkynyl, acylaminoalkynyl, mercaptoalkynyl, hydroxyalkynyl dioic acid hemi-ester or a salt thereof, or alkynyloxyalkynyl and all R 1 groups can be optionally substituted;
R 2 is N 3 ;
R 3 is hydrogen, or when a double bond is present between C4 and C5 of the steroid ring system, then R 3 is not present;
R 4 is one of hydrogen or lower alkyl,
R 5 is one of —C(O)CH 2 N 3 , —C(O)CH 2 Br, or —C(O)CH 3 ; and
the dotted lines indicate that a single or double bond may be present.
4. A compound selected from one of the following, including pharmaceutically acceptable esters, salts and acid addition salts thereof:
17β-[2-(4-tolyl)ethynyl]-5α-androstane-3α-ol;
17β-(2-methoxycarbonylethynyl)-5α-androstane-3β-ol;
17β-(2-bromoethynyl)-5α-androstane-3α-ol;
17β-(3-hydroxy-1-butynyl)-5α-androstane-3α-ol;
17β-(3-oxo-1-butynyl)-5α-androstan-3α-ol;
17β-[1-hydroxy-3-(4-methoxyphenyl)-2-propynyl]-5α-androstan-3α-ol;
17β-(1-hydroxy-2,3-butadienyl)-5α-androstane-3-ol;
17β-(1-methoxy-2-propynyl)-5α-androstan-3a-ol;
17β-(1-hydroxy-2-propynyl)-5α-androstan-3-ol;
3α-Azido-5α-pregnan-20-one;
3α-Azido-21-bromo-5α-pregnan-20-one; or
3α,21-di-azido-5α-pregnan-20-one.
5. A method of inducing anesthesia; treating stress, treating anxiety, treating pre-menstrual syndrome, treating post-natal depression, and treating seizures; ameliorating attacks of anxiety, ameliorating muscle tension, or ameliorating depression common with patients suffering from central nervous system abnormalities, comprising
administering to a patient a compound represented by Formula (I):
including pharmaceutically acceptable esters, salts and acid addition salts thereof, wherein:
R is one of hydrogen, amino, thio, sulfinyl, sulfonyl, sulfonamido, halogen, alkoxy, alkyl, alkenyl, or alkynyl and all R groups can be optionally substituted;
R 1 is one of alkyl, alkenyl, arylkynyl, alkoxyalkyl, aminoalkyl, cyano, cyanoalkyl, thiocyanoalkyl, isothiocyano, azidoalkyl, arylalkyl, arylalkenyl, aryl, arylkylalkynyl, alkanoyloxyalkynyl, heteroaryloxyalkynyl, oxoalkynyl or a ketal thereof, cyanoalkynyl, heteroarylalkynyl, hydroxyalkynyl, alkoxyalkynyl, aminoalkynyl, acylaminoalkynyl, mercaptoalkynyl, hydroxyalkynyl dioic acid hemi-ester or a salt thereof, or alkynyloxyalkynyl and all R 1 groups can be optionally substituted;
R 2 is one of hydroxyl, alkoxy, alkanoyloxy, aminocarbonyloxy, alkoxycarbonyloxy; azido, or NCS;
R 3 is hydrogen, or when a double bond is present between C4 and C5 of the steroid ring system, then R 3 is not present;
R 4 is one of hydrogen or lower alkyl,
R 5 is one of —CH(OR 6 )R 7 , —C≡C-aryl, —C≡C—CH(OR 6 )R 8 , or —C≡C—C(O)R 8 ;
R 6 is independently H, optionally substituted C 1-10 alkyl, optionally substituted C 2-10 alkenyl, optionally substituted C 2-10 alkynyl, optionally substituted aryl, optionally substituted arylkyl, optionally substituted C(O)—C 1-10 alkyl, optionally substituted C(O)—C 2-10 alkenyl, optionally substituted C(O)—C 2-10 alkynyl
R 7 is independently allene, optionally substituted alkynyl, optionally substituted arylkylalkynyl, optionally substituted alkanoyloxyalkynyl, optionally substituted heteroaryloxyalkynyl, oxoalkynyl or a ketal thereof, cyanoalkynyl, hydroxyalkynyl, alkoxyalkynyl, aminoalkynyl, acylaminoalkynyl, mercaptoalkynyl, hydroxyalkynyl dioic acid hemi-ester or a salt thereof, or alkynyloxyalkynyl;
R 8 is independently H, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, arylalkyl, aryl, all of which may be optionally substituted; and
the dotted lines indicate that a single or double bond may be present; or
a compound represented by Formula (I) above, including pharmaceutically acceptable esters, salts and acid addition salts thereof, wherein:
R is one of hydrogen, amino, thio, sulfinyl, sulfonyl, sulfonamido, halogen, alkoxy, alkyl, alkenyl, or alkynyl and all R groups can be optionally substituted;
R 1 is one of alkyl, alkenyl, arylkynyl, alkoxyalkyl, aminoalkyl, cyano, cyanoalkyl, thiocyanoalkyl, isothiocyano, azidoalkyl, arylalkyl, arylalkenyl, aryl, arylkylalkynyl, alkanoyloxyalkynyl, heteroaryloxyalkynyl, oxoalkynyl or a ketal thereof, cyanoalkynyl, heteroarylalkynyl, hydroxyalkynyl, alkoxyalkynyl, aminoalkynyl, acylaminoalkynyl, mercaptoalkynyl, hydroxyalkynyl dioic acid hemi-ester or a salt thereof, or alkynyloxyalkynyl and all R 1 groups can be optionally substituted;
R 2 is one of hydroxyl, alkoxy, alkanoyloxy, aminocarbonyloxy, alkoxycarbonyloxy; azido, or NCS;
R 3 is hydrogen, or when a double bond is present between C4 and C5 of the steroid ring system, then R 3 is not present;
R 4 is one of hydrogen or lower alkyl,
R 5 is —CH(X)—R 6 ; and
X is one of N 3 , CN, or NCS,
R 6 is independently H, optionally substituted C 1-10 alkyl, optionally substituted C 2-10 alkenyl, optionally substituted C 2-10 alkynyl, optionally substituted aryl, optionally substituted arylkyl, optionally substituted C(O)—C 1-10 alkyl, optionally substituted C(O)—C 2-10 alkenyl, optionally substituted C(O)—C 2-10 alkynyl;
and the dotted lines indicate that a single or double bond may be present; or
a compound represented by Formula (I) above, including pharmaceutically acceptable esters, salts and acid addition salts thereof, wherein:
R is one of hydrogen, amino, thio, sulfinyl, sulfonyl, sulfonamido, halogen, alkoxy, alkyl, alkenyl, or alkynyl and all R groups can be optionally substituted;
R 1 is one of alkyl, alkenyl, arylkynyl, alkoxyalkyl, aminoalkyl, cyano, cyanoalkyl, thiocyanoalkyl, isothiocyano, azidoalkyl, arylalkyl, arylalkenyl, aryl, arylkylalkynyl, alkanoyloxyalkynyl, heteroaryloxyalkynyl, oxoalkynyl or a ketal thereof, cyanoalkynyl, heteroarylalkynyl, hydroxyalkynyl, alkoxyalkynyl, aminoalkynyl, acylaminoalkynyl, mercaptoalkynyl, hydroxyalkynyl dioic acid hemi-ester or a salt thereof, or alkynyloxyalkynyl and all R 1 groups can be optionally substituted;
R 2 is N 3 ;
R 3 is hydrogen, or when a double bond is present between C4 and C5 of the steroid ring system, then R 3 is not present;
R 4 is one of hydrogen or lower alkyl,
R 5 is one of —C(O)CH 2 N 3 , —C(O)CH 2 Br, or —C(O)CH 3 ; and
the dotted lines indicate that a single or double bond may be present; or
a compound selected from one of the following, including pharmaceutically acceptable esters, salts and acid addition salts thereof:
17β-[2-(4-tolyl)ethynyl]-5α-androstane-3α-ol;
17β-(2-methoxycarbonylethynyl)-5α-androstane-3β-ol;
17β-(2-bromoethynyl)-5α-androstane-3α-ol;
17β-(3-hydroxy-1-butynyl)-5α-androstane-3α-ol;
17β-(3-oxo-1-butynyl)-5α-androstan-3α-ol;
17β-[1-hydroxy-3-(4-methoxyphenyl)-2-propynyl]-5α-androstan-3α-ol;
17β-(1-hydroxy-2,3-butadienyl)-5α-androstane-3-ol;
17β-(1-methoxy-2-propynyl)-5α-androstan-3a-ol;
17β-(1-hydroxy-2-propynyl)-5α-androstan-3-ol;
3α-Azido-5α-pregnan-20-one;
3α-Azido-21-bromo-5α-pregnan-20-one; or
3α,21-di-azido-5α-pregnan-20-one.
6. The method of claim 5 comprising the step of stimulating the GABA A receptor.
7. The method of claim 6 wherein;
R is one of hydrogen, amino, thio, sulfinyl, sulfonyl, sulfonamido, halogen, alkoxy, alkyl, alkenyl, or alkynyl and all R groups can be optionally substituted;
R 1 is one of alkyl, alkenyl, arylkynyl, alkoxyalkyl, aminoalkyl, cyano, cyanoalkyl, thiocyanoalkyl, isothiocyano, azidoalkyl, arylalkyl, arylalkenyl, aryl, arylkylalkynyl, alkanoyloxyalkynyl, heteroaryloxyalkynyl, oxoalkynyl or a ketal thereof, cyanoalkynyl, heteroarylalkynyl, hydroxyalkynyl, alkoxyalkynyl, aminoalkynyl, acylaminoalkynyl, mercaptoalkynyl, hydroxyalkynyl dioic acid hemi-ester or a salt thereof, or alkynyloxyalkynyl and all R 1 groups can be optionally substituted;
R 2 is one of hydroxyl, alkoxy, alkanoyloxy, aminocarbonyloxy, alkoxycarbonyloxy; azido, or NCS;
R 3 is hydrogen, or when a double bond is present between C4 and C5 of the steroid ring system, then R 3 is not present;
R 4 is one of hydrogen or lower alkyl,
R 5 is one of —CH(OR 6 )R 7 , —C≡C-aryl, —C≡C—CH(OR 6 )R 8 , or —C≡C—C(O)R 8 ;
R 6 is independently H, optionally substituted C 1-10 alkyl, optionally substituted C 2-10 alkenyl, optionally substituted C 2-10 alkynyl, optionally substituted aryl, optionally substituted arylkyl, optionally substituted C(O)—C 1-10 alkyl, optionally substituted C(O)—C 2-10 alkenyl, optionally substituted C(O)—C 2-10 alkynyl
R 7 is independently allene, optionally substituted alkynyl, optionally substituted arylkylalkynyl, optionally substituted alkanoyloxyalkynyl, optionally substituted heteroaryloxyalkynyl, oxoalkynyl or a ketal thereof, cyanoalkynyl, hydroxyalkynyl, alkoxyalkynyl, aminoalkynyl, acylaminoalkynyl, mercaptoalkynyl, hydroxyalkynyl dioic acid hemi-ester or a salt thereof, or alkynyloxyalkynyl;
R 8 is independently H, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, arylalkyl, or aryl, all of which may be optionally substituted; and
the dotted lines indicate that a single or double bond may be present.
8. The method of claim 6 wherein;
R is one of hydrogen, amino, thio, sulfinyl, sulfonyl, sulfonamido, halogen, alkoxy, alkyl, alkenyl, or alkynyl and all R groups can be optionally substituted;
R 1 is one of alkyl, alkenyl, arylkynyl, alkoxyalkyl, aminoalkyl, cyano, cyanoalkyl, thiocyanoalkyl, isothiocyano, azidoalkyl, arylalkyl, arylalkenyl, aryl, arylkylalkynyl, alkanoyloxyalkynyl, heteroaryloxyalkynyl, oxoalkynyl or a ketal thereof, cyanoalkynyl, heteroarylalkynyl, hydroxyalkynyl, alkoxyalkynyl, aminoalkynyl, acylaminoalkynyl, mercaptoalkynyl, hydroxyalkynyl dioic acid hemi-ester or a salt thereof, or alkynyloxyalkynyl and all R 1 groups can be optionally substituted;
R 2 is one of hydroxyl, alkoxy, alkanoyloxy, aminocarbonyloxy, alkoxycarbonyloxy; azido, or NCS;
R 3 is hydrogen, or when a double bond is present between C4 and C5 of the steroid ring system, then R 3 is not present;
R 4 is one of hydrogen or lower alkyl,
R 5 is —CH(X)—R 6 ; and
X is one of N 3 , CN, or NCS,
R 6 is independently H, optionally substituted C 1-10 alkyl, optionally substituted C 2-10 alkenyl, optionally substituted C 2-10 alkynyl, optionally substituted aryl, optionally substituted arylkyl, optionally substituted C(O)—C 1-10 alkyl, optionally substituted C(O)—C 2-10 alkenyl, optionally substituted C(O)—C 2-10 alkynyl;
and the dotted lines indicate that a single or double bond may be present.
9. The method of claim 6 wherein;
R is one of hydrogen, amino, thio, sulfinyl, sulfonyl, sulfonamido, halogen, alkoxy, alkyl, alkenyl, or alkynyl and all R groups can be optionally substituted;
R 1 is one of hydrogen, alkyl, alkenyl, arylkynyl, alkoxyalkyl, aminoalkyl, cyano, cyanoalkyl, thiocyanoalkyl, isothiocyano, azidoalkyl, arylalkyl, arylalkenyl, aryl, arylkylalkynyl, alkanoyloxyalkynyl, heteroaryloxyalkynyl, oxoalkynyl or a ketal thereof, cyanoalkynyl, heteroarylalkynyl, hydroxyalkynyl, alkoxyalkynyl, aminoalkynyl, acylaminoalkynyl, mercaptoalkynyl, hydroxyalkynyl dioic acid hemi-ester or a salt thereof, or alkynyloxyalkynyl and all R 1 groups can be optionally substituted;
R 2 is N 3 ;
R 3 is hydrogen, or when a double bond is present between C4 and C5 of the steroid ring system, then R 3 is not present;
R 4 is one of hydrogen or lower alkyl,
R 5 is one of —C(O)CH 2 N 3 , —C(O)CH 2 Br, or —C(O)CH 3 ; and
the dotted lines indicate that a single or double bond may be present.
10. The method of claim 6 wherein; the compound is selected from:
17β-[2-(4-tolyl)ethynyl]-5α-androstane-3α-ol;
17β-(2-methoxycarbonylethynyl)-5α-androstane-3β-ol;
17β-(2-bromoethynyl)-5α-androstane-3α-ol;
17β-(3-hydroxy-1-butynyl)-5α-androstane-3α-ol;
17β-(3-oxo-1-butynyl)-5α-androstan-3α-ol;
17β-[1-hydroxy-3-(4-methoxyphenyl)-2-propynyl]-5α-androstan-3α-ol;
17β-(1-hydroxy-2,3-butadienyl)-5α-androstane-3-ol;
17β-(1-methoxy-2-propynyl)-5α-androstan-3a-ol;
17β-(1-hydroxy-2-propynyl)-5α-androstan-3-ol;
3α-Azido-5α-pregnan-20-one;
3α-Azido-21-bromo-5α-pregnan-20-one; or
3α,21-di-azido-5α-pregnan-20-one.
11. The method of claim 5 wherein;
R is one of hydrogen, amino, thio, sulfinyl, sulfonyl, sulfonamido, halogen, alkoxy, alkyl, alkenyl, or alkynyl and all R groups can be optionally substituted;
R 1 is one of alkyl, alkenyl, arylkynyl, alkoxyalkyl, aminoalkyl, cyano, cyanoalkyl, thiocyanoalkyl, isothiocyano, azidoalkyl, arylalkyl, arylalkenyl, aryl, arylkylalkynyl, alkanoyloxyalkynyl, heteroaryloxyalkynyl, oxoalkynyl or a ketal thereof, cyanoalkynyl, heteroarylalkynyl, hydroxyalkynyl, alkoxyalkynyl, aminoalkynyl, acylaminoalkynyl, mercaptoalkynyl, hydroxyalkynyl dioic acid hemi-ester or a salt thereof, or alkynyloxyalkynyl and all R 1 groups can be optionally substituted;
R 2 is one of hydroxyl, alkoxy, alkanoyloxy, aminocarbonyloxy, alkoxycarbonyloxy; azido, or NCS;
R 3 is hydrogen, or when a double bond is present between C4 and C5 of the steroid ring system, then R 3 is not present;
R 4 is one of hydrogen or lower alkyl,
R 5 is one of —CH(OR 6 )R 7 , —C≡C-aryl, —C≡C—CH(OR 6 )R 8 , or —C≡C—C(O)R 8 ;
R 6 is independently H, optionally substituted C 1-10 alkyl, optionally substituted C 2-10 alkenyl, optionally substituted C 2-10 alkynyl, optionally substituted aryl, optionally substituted arylkyl, optionally substituted C(O)—C 1-10 alkyl, optionally substituted C(O)—C 2-10 alkenyl, optionally substituted C(O)—C 2-10 alkynyl
R 7 is independently allene, optionally substituted alkynyl, optionally substituted arylkylalkynyl, optionally substituted alkanoyloxyalkynyl, optionally substituted heteroaryloxyalkynyl, oxoalkynyl or a ketal thereof, cyanoalkynyl, hydroxyalkynyl, alkoxyalkynyl, aminoalkynyl, acylaminoalkynyl, mercaptoalkynyl, hydroxyalkynyl dioic acid hemi-ester or a salt thereof, or alkynyloxyalkynyl;
R 8 is independently H, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, arylalkyl, or aryl, all of which may be optionally substituted; and
the dotted lines indicate that a single or double bond may be present.
12. The method of claim 5 wherein;
R is one of hydrogen, amino, thio, sulfinyl, sulfonyl, sulfonamido, halogen, alkoxy, alkyl, alkenyl, or alkynyl and all R groups can be optionally substituted;
R 1 is one of alkyl, alkenyl, arylkynyl, alkoxyalkyl, aminoalkyl, cyano, cyanoalkyl, thiocyanoalkyl, isothiocyano, azidoalkyl, arylalkyl, arylalkenyl, aryl, arylkylalkynyl, alkanoyloxyalkynyl, heteroaryloxyalkynyl, oxoalkynyl or a ketal thereof, cyanoalkynyl, heteroarylalkynyl, hydroxyalkynyl, alkoxyalkynyl, aminoalkynyl, acylaminoalkynyl, mercaptoalkynyl, hydroxyalkynyl dioic acid hemi-ester or a salt thereof, or alkynyloxyalkynyl and all R 1 groups can be optionally substituted;
R 2 is one of hydroxyl, alkoxy, alkanoyloxy, aminocarbonyloxy, alkoxycarbonyloxy; azido, or NCS;
R 3 is hydrogen, or when a double bond is present between C4 and C5 of the steroid ring system, then R 3 is not present;
R 4 is one of hydrogen or lower alkyl,
R 5 is —CH(X)—R 6 ; and
X is one of N 3 , CN, or NCS,
R 6 is independently H, optionally substituted C 1-10 alkyl, optionally substituted C 2-10 alkenyl, optionally substituted C 2-10 alkynyl, optionally substituted aryl, optionally substituted arylkyl, optionally substituted C(O)—C 1-10 alkyl, optionally substituted C(O)—C 2-10 alkenyl, optionally substituted C(O)—C 2-10 alkynyl;
and the dotted lines indicate that a single or double bond may be present.
13. The method of claim 5 wherein;
R is one of hydrogen, amino, thio, sulfinyl, sulfonyl, sulfonamido, halogen, alkoxy, alkyl, alkenyl, or alkynyl and all R groups can be optionally substituted;
R 1 is one of hydrogen, alkyl, alkenyl, arylkynyl, alkoxyalkyl, aminoalkyl, cyano, cyanoalkyl, thiocyanoalkyl, isothiocyano, azidoalkyl, arylalkyl, arylalkenyl, aryl, arylkylalkynyl, alkanoyloxyalkynyl, heteroaryloxyalkynyl, oxoalkynyl or a ketal thereof, cyanoalkynyl, heteroarylalkynyl, hydroxyalkynyl, alkoxyalkynyl, aminoalkynyl, acylaminoalkynyl, mercaptoalkynyl, hydroxyalkynyl dioic acid hemi-ester or a salt thereof, or alkynyloxyalkynyl and all R 1 groups can be optionally substituted;
R 2 is N 3 ;
R 3 is hydrogen, or when a double bond is present between C4 and C5 of the steroid ring system, then R 3 is not present;
R 4 is one of hydrogen or lower alkyl,
R 5 is one of —C(O)CH 2 N 3 , —C(O)CH 2 Br, or —C(O)CH 3 ; and
the dotted lines indicate that a single or double bond may be present.
14. The method of claim 5 wherein; the compound is selected from:
17β-[2-(4-tolyl)ethynyl]-5α-androstane-3α-ol;
17β-(2-methoxycarbonylethynyl)-5α-androstane-3β-ol;
17β-(2-bromoethynyl)-5α-androstane-3α-ol;
17β-(3-hydroxy-1-butynyl)-5α-androstane-3α-ol;
17β-(3-oxo-1-butynyl)-5α-androstan-3α-ol;
17β-[1-hydroxy-3-(4-methoxyphenyl)-2-propynyl]-5α-androstan-3α-ol;
17β-(1-hydroxy-2,3-butadienyl)-5α-androstane-3-ol;
17β-(1-methoxy-2-propynyl)-5α-androstan-3a-ol;
17β-(1-hydroxy-2-propynyl)-5α-androstan-3-ol;
3α-Azido-5α-pregnan-20-one;
3α-Azido-21-bromo-5α-pregnan-20-one; or
3α,21-di-azido-5α-pregnan-20-one.